BTK inhibitor

Phase 1Small molecule

Ascentage Pharma Group Inc.

BTK inhibitor is one of 114 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell LymphomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Atrial FibrillationActive, not recruiting

Mantle Cell LymphomaPhase 1

Active, not recruiting

Chronic Lymphocytic LeukemiaPreclinical

Active, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Calquence

AstraZeneca

Preclinical

1 2

Rituxan

Calan

4 4

Brukinsa

BBeOne Medicines

Preclinical

1 5

Imbruvica

PPharmacyclics LLC.

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 9

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Monotherapy

NCT06476899

Q4 2027

Phase 3Recruiting

CLL/SLL

NCT06104566

Not yet recruiting

Chronic Lymphocytic Leukemia

NCT06557304

Q1 2028

Phase 1Recruiting

Mantle Cell Lymphoma

NCT06675123

Clinical

Trials by Indication[1]

R/R B-NHL1 trial

A Combination Study of CAR-T Therapy in r/r B-NHL

Unknown status·RRuijin Hospital·Phase 2·NCT05871684·48 enrolled

Chronic Lymphocytic Leukemia1 trial

The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China

Not yet recruiting·PPeking University People's Hospital··NCT06557304·1,000 enrolled

Treatment1 trial

Current Status of BTKi Treatment for CLL/SLL in China

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT06508684·1,000 enrolled

Mantle Cell Lymphoma1 trial

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recruiting·—·Phase 1·NCT06675123·10 enrolled

Atrial Fibrillation1 trial

Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

Active, not recruiting·UUniversity Hospital, Caen··NCT06561243·15,000 enrolled

2 more indications

Monotherapy1 trial

A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

Not yet recruiting·FFei Li·Phase 2·NCT06476899·60 enrolled

CLL/SLL1 trial

Global Trial in APG2575 for Patients With CLL/SLL

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 3·NCT06104566·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BTK inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BTK inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BTK inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascentage Pharma Group Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Ascentage Pharma Group Inc.

BTK inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Trials by Indication[1]

R/R B-NHL1 trial

Chronic Lymphocytic Leukemia1 trial

Treatment1 trial

Mantle Cell Lymphoma1 trial

Atrial Fibrillation1 trial

Monotherapy1 trial

CLL/SLL1 trial

References

Drug Info

Quick Facts

Related News